

REMARKS

By the present amendment, new claims 111-114 are presented which provide for controlled release Galenical formulation of Claim 14 or 44 to be in capsule or tablet form. These claims find explicit support in the as-filed disclosure, and the original claims, *e.g.*, claims 7 and 8.

Applicants note that this application has been refiled so that Applicants may submit a declaration by an expert in the art and conduct an interview with Examiner Tran to discuss the outstanding issues in this application. This interview is set to take place on February 22, 2005 at 1:00 P.M. as agreed to by Supervisory Examiner Page on behalf of Examiner Tran.

The outstanding rejections stand traversed for the reasons of record, *e.g.*, as set forth in the Applicants' Reply to the non-final rejection dated November 18, 2002.


If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and

please charge any deficiency in fees or credit any overpayments to Deposit
Account No. 05-1323 (Docket #100338.55780US).

Respectfully submitted,

January 26, 2005



Robin L. Teskin
Registration No. 35,030

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
RLT:elew

357576